About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

At the moment the company generates 11M USD in revenues.

On its last earning announcement, the company reported a loss of -0.95$ per share.

The book value per share is 0.79$

Celldex Therapeutics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
11M - -61M -543.10% -146M -0.95 - - 147M 0.79 -79M -1M -80M